A

Akebia Therapeutics
D

AKBA

1.26500
USD
-0.05
(-3.44%)
Market Closed
Volume
90,311
EPS
-0
Div Yield
-
P/E
-16
Market Cap
339,346,677
Overview
Related Instruments
A
ALKS
D
52.560
-0.270(-0.51%)
53.250+0.690(+1.31%)
GSK
GSK
D
50.770
-0.004(-0.01%)
51.430+0.660(+1.30%)
INCY
INCY
D
115.780
-1.540(-1.31%)
JNJ
JNJ
D
255.64
4.98(1.98%)
252.00-3.64(-1.42%)
O
OPK
D
1.18500
-0.03500(-2.87%)
1.23000+0.04500(+3.80%)
VRTX
VRTX
D
472.74
-9.11(-1.89%)
More

Title: Akebia Therapeutics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Smarter Decisions,Together
FacebookTwitterYoutubeLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.